# Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)

> **NCT07191145** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 80 (estimated)

## Conditions studied

- Post Traumatic Headache

## Interventions

- **DRUG:** Eptinezumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07191145
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07191145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07191145, "Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07191145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*